AU722882B2 - Anti-CD6 monoclonal antibodies and their uses - Google Patents

Anti-CD6 monoclonal antibodies and their uses Download PDF

Info

Publication number
AU722882B2
AU722882B2 AU76905/96A AU7690596A AU722882B2 AU 722882 B2 AU722882 B2 AU 722882B2 AU 76905/96 A AU76905/96 A AU 76905/96A AU 7690596 A AU7690596 A AU 7690596A AU 722882 B2 AU722882 B2 AU 722882B2
Authority
AU
Australia
Prior art keywords
ser
gly
thr
leu
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU76905/96A
Other languages
English (en)
Other versions
AU7690596A (en
Inventor
Josefa Lombardero Valladares
Jose Enrique Montero Casimiro
Rolando Perez Rodriguez
Patricia Sierra Blazquez
Blanca Rosa Tormo Bravo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Immunologia Molecular
Original Assignee
Centro de Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Immunologia Molecular filed Critical Centro de Immunologia Molecular
Publication of AU7690596A publication Critical patent/AU7690596A/en
Assigned to CENTRO DE INMUNOLOGIA MOLECULAR reassignment CENTRO DE INMUNOLOGIA MOLECULAR Amend patent request/document other than specification (104) Assignors: CENTRO DE INMUNOLOGIA MOLECULAR
Application granted granted Critical
Publication of AU722882B2 publication Critical patent/AU722882B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU76905/96A 1995-11-17 1996-11-18 Anti-CD6 monoclonal antibodies and their uses Ceased AU722882B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
CU120/95 1995-11-17
PCT/CU1996/000004 WO1997019111A2 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 y sus utilizaciones

Publications (2)

Publication Number Publication Date
AU7690596A AU7690596A (en) 1997-06-11
AU722882B2 true AU722882B2 (en) 2000-08-10

Family

ID=5459401

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76905/96A Ceased AU722882B2 (en) 1995-11-17 1996-11-18 Anti-CD6 monoclonal antibodies and their uses

Country Status (15)

Country Link
US (1) US6572857B1 (https=)
EP (1) EP0807125B1 (https=)
JP (1) JP4113929B2 (https=)
KR (1) KR100533854B1 (https=)
CN (1) CN1222540C (https=)
AT (1) ATE280783T1 (https=)
AU (1) AU722882B2 (https=)
BR (1) BRPI9607171B1 (https=)
CA (1) CA2210751C (https=)
CU (1) CU22584A1 (https=)
DE (1) DE69633717T2 (https=)
DK (1) DK0807125T3 (https=)
ES (1) ES2231826T3 (https=)
PT (1) PT807125E (https=)
WO (1) WO1997019111A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1054316A1 (zh) * 2000-05-26 2003-11-28 Smithkline Beecham Corporation 用於治疗rank配体介导疾病的抗-rank配体单克隆抗体
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
US20070003568A1 (en) 2003-02-24 2007-01-04 Alice Dautry-Varsat Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof
KR101482956B1 (ko) * 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 류마티스 관절염의 진단 및 치료에 사용되는 항-ｃｄ6 단일클론성 항체를 포함하는 약학 조성물
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
CA2711394A1 (en) 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
WO2009113083A1 (en) * 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
RS57215B1 (sr) * 2010-07-15 2018-07-31 Adheron Therapeutics Inc Humanizovana antitela koja ciljaju ec1 domen kadherina-11 i kompozicije i postupci koji su u vezi sa njima
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
BR112013033988B1 (pt) 2011-07-01 2021-10-19 Beckman Coulter, Inc. Métodos de identificação e isolamento de uma ou mais populações de células t regulatórias imunossupressoras
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
FR3000216B1 (fr) * 2012-12-21 2015-02-06 Galderma Res & Dev Utilisation de proteases particulieres pour la detection de trichophytons et de pathologies associees
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3024485B1 (en) 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN105504062B (zh) * 2015-12-25 2019-06-04 百泰生物药业有限公司 一种抗CD6单抗T1h的检测性抗体及应用
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
CN112424226B (zh) * 2018-02-27 2025-03-14 平衡生物科技股份有限公司 用于治疗重度哮喘的抗cd6抗体
US12281151B2 (en) 2018-06-29 2025-04-22 City Of Hope CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
BR112021016967A2 (pt) 2019-02-26 2021-11-23 Equillium Inc Composições de anticorpo anti-cd6 e métodos para tratar lúpus
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
CA3231281A1 (en) 2021-09-08 2023-03-16 Yanelda De Los Angeles Garcia Vega Use of anti-cd6 monoclonal antibodies in the prevention of cellular and organ damage resulting from hyper-inflammatory response
WO2025096685A1 (en) 2023-10-30 2025-05-08 City Of Hope Methods of making and using regulatory t cells for treatment of autoimmune disorders and cancers
CN120005027B (zh) * 2025-04-10 2025-09-23 中国水产科学研究院长江水产研究所 大口黑鲈cd6抗原结合肽、及其单克隆抗体和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012614A1 (en) * 1993-11-02 1995-05-11 Duke University Cd6 ligand

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012614A1 (en) * 1993-11-02 1995-05-11 Duke University Cd6 ligand

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELLULAR IMMUNOLOGY, VOL. 154, 1994, PP123-133 *
IMMUNOTECHNOLOGY, VOL. 1, 1995, PP107-113 *

Also Published As

Publication number Publication date
BRPI9607171B1 (pt) 2016-07-19
CU22584A1 (es) 1999-11-03
CN1222540C (zh) 2005-10-12
AU7690596A (en) 1997-06-11
KR100533854B1 (ko) 2006-09-20
DE69633717D1 (de) 2004-12-02
WO1997019111A2 (es) 1997-05-29
ES2231826T3 (es) 2005-05-16
BR9607171A (pt) 1997-11-11
JPH11506017A (ja) 1999-06-02
EP0807125B1 (en) 2004-10-27
WO1997019111A3 (es) 1998-02-12
PT807125E (pt) 2005-03-31
CA2210751A1 (en) 1997-05-29
KR19980701502A (ko) 1998-05-15
DE69633717T2 (de) 2006-02-02
DK0807125T3 (da) 2005-03-14
EP0807125A2 (en) 1997-11-19
ATE280783T1 (de) 2004-11-15
JP4113929B2 (ja) 2008-07-09
MX9705445A (es) 1998-06-30
CA2210751C (en) 2007-01-30
CN1175957A (zh) 1998-03-11
US6572857B1 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
AU722882B2 (en) Anti-CD6 monoclonal antibodies and their uses
US6316227B1 (en) Nucleic acids encoding interleukin-5 specific recombinant antibodies
US6180377B1 (en) Humanized antibodies
RU2112037C1 (ru) Гибридное моноклональное антитело, взаимодействующее с cd4-антигеном т-хелперных клеток человека, и способ его получения
AU2006301163B2 (en) Compositions and methods for treating proliferative disorders
KR101078459B1 (ko) 항 수초 관련 당단백질 항체
Co et al. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody
DE69535243T2 (de) Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
EP0781845B1 (en) Anti-human milk fat globule humanised antibodies and processes for their production
US20020065398A1 (en) Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (egf-r); diagnostic and therapeutic use
WO1997019111A9 (es) Anticuerpos monoclonales anti-cd6 y sus utilizaciones
EP0807125A1 (en) Monoclonal antibodies anti-cd6 and their uses
CA2129445A1 (en) Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
WO2001064754A1 (en) Gene recombinant antibody and its fragment
HU230197B1 (hu) Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre
JP2008253267A (ja) 改変抗体可変領域の調製のための物質ならびにその治療的用途
CA2812856A1 (en) Interleukin-10 antibodies
JP2002506420A (ja) 変異した不活化ＩｇＧ２ドメインおよびこれを組み込んだ抗ＣＤ３抗体
JPH09512705A (ja) Ｅ−セレクチンに対する抗体
DE69029970T2 (de) Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
AU719369B2 (en) Monoclonal antiidiotypic antibodies (AB2) and their uses
USRE39548E1 (en) Interleukin-5 specific recombinant antibodies
RU2840044C1 (ru) Антитела к собачьему альфа-рецептору интерлейкина-4
RU2838943C1 (ru) Антитела к собачьему альфа-рецептору интерлейкина-4
EP4052727A1 (en) Immune response suppressor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired